Sentences with phrase «of acute leukemia patients»

Not exact matches

The original pharmaceutical company was in the process of developing Annamycin, a drug that selectively kills highly resistant tumors, especially patients suffering from AML (Acute Myeloid Leukemia).

Juno Therapeutics will resume its Phase II ROCKET clinical trial of its acute lymphoblastic leukemia candidate JCAR015 following the FDA's lifting of a partial clinical hold imposed last week following the deaths of three patients.

For the second time in 5 months, Juno Therapeutics has put a clinical hold on a Phase II trial of JCAR015 in adult patients with relapsed or refractory B - cell acute lymphoblastic leukemia due to patient deaths.

Juno Therapeutics is seeking to change the protocol for the Phase II ROCKET clinical trial of its acute lymphoblastic leukemia candidate JCAR015, which the FDA has placed on clinical hold following the deaths of three patients, two of them last week.

Targeting exhausted immune cells may change the prognosis for patients with acute myeloid leukemia (AML) relapse after a stem cell transplant, according to Penn State College of Medicine researchers.

Despite improved therapy, only one out of every two adult patients survive acute myeloid leukemia (AML).

Changes in the genetic code (mutations) that reduce TET2 function are found in 10 percent of patients with acute myeloid leukemia (AML), 30 percent of those with a form of pre-leukemia called myelodysplastic syndrome, and in nearly 50 percent of patients with chronic myelomonocytic leukemia.

A protein domain once considered of little importance may be key to helping patients who are fighting acute myeloid leukemia (AML) avoid a relapse.

After seeing promising results in phase 1 of the Pediatric Leukemia Adoptive Therapy (PLAT - 02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 Leukemia Adoptive Therapy (PLAT - 02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 percent.

It is activated in 50 to 80 percent of patients with acute myelogenous leukemia (AML), and in some, but not all cases, is associated with genetic mutations.

Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found a chemical «signature» in blood - forming stem cells that predicts whether patients with acute myeloid leukemia (AML) will respond to chemotherapy.

Researchers at University of California San Diego School of Medicine and Moores Cancer Center have identified RNA - based biomarkers that distinguish between normal, aging hematopoietic stem cells and leukemia stem cells associated with secondary acute myeloid leukemia (sAML), a particularly problematic disease that typically afflicts older patients who have often already experienced a bout with cancer.

However, about 15 percent of patients on immunosuppressives develop cancer of the blood — acute leukemia and myelodysplastic syndromes — months or years following treatment.

«Personalized cellular therapy achieves complete remission in 90 percent of acute lymphoblastic leukemia patients studied.»

Noelle Frey, MD, an assistant professor of Hematology - Oncology, will present results in 27 adult patients with acute lymphoblastic leukemia (ALL), identifying an optimal dose and infusion regimen that should improve treatment response while reducing potential for side effects.

His group was the first to publish findings of dramatic molecular remissions in patients with chemorefractory acute lymphoblastic leukemia following treatment with autologous CD19 - targeted T cells.

• A patient with blood cancer who had received several diagnoses was found, through testing, to have an unusual form of acute myeloid leukemia (AML), which predicted responsiveness to imatinib.

Researchers can now tag individual malignant cells in the bone marrow of patients with acute myeloid leukemia.

Herbert OettgenCRI CONNECTIONCVC MEMBERSCIENTIFIC ADVISOR reports the first treatment of patients with acute lymphoblastic leukemia with L - asparaginase.

A Phase 3 Open - label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

A Phase 1/2, Multicenter, Open - label Study of FT - 2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

A Phase 1, Multicenter, Open - Label, Safety Study of AG - 120 or AG - 221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and / or IDH2 Mutation

A Biomarker - Directed Phase 2 Trial of SY - 1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

A Phase I - II Randomized Trial of a Combination of Nintedanib / Placebo in Combination with Induction Chemotherapy for Patients with Refractory or First Relapse Acute Myeloid Leukemia

The patient was treated on an acute lymphoblastic leukemia (ALL) protocol for eight cycles of hyperCVAD (cyclophosphamide, vincristine, adriamycin and decadron) alternating with MTX / Ara - C (methotrexate and cytarabine) and achieved complete remission (CR) confirmed by a bone marrow biopsy and by the resolution of most of her skin lesions.

Removal of a fifth course of chemotherapy containing cytarabine resulted in worse overall survival and disease - free survival in pediatric patients with low - risk acute myeloid leukemia (AML), according to the results (abstract 10515) of a pooled analysis of two Children's Oncology Group (COG) trials presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2 — 6 in Chicago.

Patients with a rare type of leukemia called acute promyelocytic leukemia (APL) have better outcomes than most leukemias because they can be treated with a very...

A Case of Therapy - Related Acute Myeloid Leukemia in a Patient With Heterozygous Mutations in the Ataxia Telangiectasia Mutated Gene

Final results of a cohort from a phase II monotherapy trial of quizartinib in acute myeloid leukemia patients showed that more than half of patients 60 years of age and older who harbored an internal tandem duplication in the FMS - like tyrosine kinase 3 had a composite complete remission.

The use of minimal residual disease (MRD) provided a more objective measure of induction failure in patients with pediatric acute lymphoblastic leukemia (ALL) than did morphology, according to the results of a study published recently in the Journal of Clinical Oncology.

Relapsed or refractory chronic lymphocytic leukemia and acute lymphoblastic leukemia patients have shown durable responses of almost 2 years to a novel T - cell engineering technique developed at the University of Pennsylvania Perelman School of Medicine in Philadelphia.

Study finds age, ancestry and genetics can influence the risk of pancreatitis, a serious chemo side effect in acute lymphoblastic leukemia patients.

There was scant experimental evidence for this hypothesis until 1994, when John Dick and colleagues demonstrated that leukemia - initiating stem cells (LSCs) present in the blood of leukemia patients may induce acute myelogenous leukemia (AML) when transplanted into severe combined immunodeficient mice (2).

About one - half (45 %) of patients were enrolled in lymphoma trials, one - quarter (24 %) in chronic myeloid leukemia (CML) trials or multiple myeloma trials (22 %), and 2 % of patients were enrolled in trials of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Endari, the first new treatment for patients with sickle cell disease in almost 20 years, Genentech's Hemlibra, the first - ever non-blood product to treat patients with hemophilia A with inhibitors, Actemra, the first treatment for adults diagnosed with giant cell arteritis, BioMarin's Brineura, the first treatment for a form of Batten disease, Benznidazole, the first U.S. treatment for Chagas disease, Novartis» Kymriah to treat certain children and young adults with B - cell acute lymphoblastic leukemia, which is also the first gene therapy to become available in the United States, are some of the drugs that received the FDA's stamp of approval in 2017.

Our intentions are noble — put patients at the forefront of our myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) investigations to make their cure today's reality.

As many as 30 percent of patients who survive childhood Hodgkin lymphoma develop a secondary cancer after diagnosis, primarily breast cancer, non-Hodgkin lymphoma, thyroid cancer or acute leukemia.

Building on proof - of - principle experimentation in mice bearing CD19 + malignancies, the MSKCC team led by Dr. Sadelain has recently obtained dramatic clinical responses in adult patients with acute lymphoblastic leukemia.

May 30, 2015 Khoury et al ASCO AST - VAC1 Presentation Long - term Follow - up of Patients with Acute Myelogenous Leukemia Receiving an Autologous Telomerase - based Dendritic Cell Vaccine

To evaluate the impact of VPA treatment on the preservation of GVL activity, we challenged BALB / c recipients with host - type GFP + acute myeloid leukemia cells (H - 2d) to mimic residual leukemia in patients receiving allogeneic BMT.

Whole genome and whole transcriptome sequencing of 31 pediatric Asian patients with T - cell acute lymphoblastic leukemia found that about 10 percent had the same alteration in a non-coding region of DNA.

The first project focuses on frequent somatic mutations of any of several splicing factors that are found in patients with myelodysplastic syndrome or acute myeloid leukemia.

Arsenic trioxide (ATO) consolidation was well tolerated in pediatric patients with acute promyelocytic leukemia (APL) and allowed for significant reductions in cumulative anthracycline doses, according to the results of the Children's Oncology Group AAML0631 trial published in the Journal of Clinical Oncology.

In 2005, the identification of an activating mutation in JAK2 (the V617F mutation) as a STAT5 - activating and disease - causing genetic alteration in a significant proportion of patients with myeloproliferative neoplasms (MPNs) has emphasized the oncogenic role of the JAK tyrosine kinases in hematologic malignancies.2 — 5 JAK2 is a member of the Janus tyrosine kinase family comprising three other mammalian non-receptor tyrosine kinases (JAK1, JAK3 and TYK2) that associate with cytokine receptors lacking intrinsic kinase activity to mediate cytokine - induced signal transduction and activation of STAT transcription factors.6 All JAKs share a similar protein structure and contain a tyrosine kinase domain at the C - terminus flanked by a catalytically inactive pseudokinase domain with kinase - regulatory activity, by an atypical SH2 domain and by a FERM domain that mediates association to the membrane - proximal region of the cytokine receptors.7, 8 Soon after the discovery of JAK2 V617F, we and others described that activating JAK1 mutations are relatively common in adult patients with T - cell acute lymphoblastic leukemia (ALL) and participate in ALL development allowing for constitutive activation of STAT5.9 — 11 Several STAT5 - activating JAK1 mutations were also reported in AML and breast cancer patients.10

In a patient with relapsed B - cell acute lymphoblastic leukemia, a single dose of 5 × 10 (4) / kg 1928zT2 T cells resulted in robust expansion and leukemia eradication and led to complete remission.

20 - 30 % of patients with acute myeloid leukemia have mutations of the FLT3 biomarker that make them eligible for several FLT3 - targeted small molecule therapies currently in late stage clinical trials.

«The data show that aberrant epigenetic gene programming can now be considered a hallmark of acute lymphoblastic leukemia, occurring in all patients regardless of the presence of genetic mutations,» Melnick said.

Elevated numbers of circulating CD34 (+) cells were found in p.P214L and p.Y401N carriers, and two patients from different families suffered from refractory anemia with excess blasts, while one patient from a third family was successfully treated for acute myeloid leukemia.

The new results — from trials for patients with advanced lymphoma, multiple myeloma, and pancreatic cancer — expand on Penn's work with chimeric antigen receptor (CAR) therapies, building on findings in patients with chronic lymphocytic leukemia and acute lymphoblastic leukemia dating back to the start of the first clinical trial in 2010.

Acute myeloid leukemia (AML) is the leading cause of leukemia mortality in the United States.1 Curative treatment involves intensive induction chemotherapy, before proceeding to either consolidation chemotherapy or allogeneic stem cell transplantation based on the patient's risk for relapse.2 This approach has been employed for > 4 decades and, although most individuals achieve complete remissions with front - line therapy, 3 the majority of patients ultimately relapse with drug - resistant disease, and overall survival rates remain disappointingly poor.4 The limited ability of many patients to tolerate the intense chemotherapy - based treatments, in particular hematological toxicity, further contributes to the poor outcomes noted in this disease.